The Justice Department moved certain FDA-approved and state-licensed marijuana products to Schedule III, and will fast-track broader marijuana rescheduling talks.
The Justice Department has taken a major step that could reshape how some marijuana products are handled under federal law—without fully changing marijuana’s federal status.
On Thursday. acting Attorney General Todd Blanche signed an order directing that certain marijuana products be moved from Schedule I to Schedule III of the Controlled Substances Act.. The order applies to marijuana. marijuana extracts. and marijuana-derived compounds—such as delta-9 THC—when those products are either included in an FDA-approved drug product or are covered by a state medical marijuana license for medical purposes.
The practical result is a narrower easing of restrictions for a defined set of products already operating in a regulated medical pipeline.. Schedule I is the strictest federal category. used for drugs that regulators say have a high potential for abuse and the potential for severe psychological or physical dependence.. Schedule III, by contrast, is reserved for substances described as having a moderate to low potential for dependence.
What the DOJ order changes—and what it doesn’t
The order draws a careful line.. “Any form of marijuana” outside an FDA-approved drug product, or outside a state medical marijuana license, remains Schedule I.. That distinction matters for people and businesses that handle marijuana outside the medical framework the order recognizes. because they continue to face the full federal penalties and enforcement risks tied to Schedule I.
For the products that do qualify. the Justice Department says the change is designed to better align federal rules with the reality that medical marijuana is already regulated at the state level.. The order also emphasizes that federal handling requirements will apply for Schedule III drugs.. Those include DEA registration for certain entities, and compliance obligations for disposal, security, and labeling.
That means the move isn’t a blanket federal legalization or decriminalization. Instead, it is a targeted shift intended to open the door for more research and clearer federal pathways for medical use—while still keeping tight controls on the rest.
The expedited path to broader rescheduling
The order also comes with an accelerated process for the Biden-era stalemate on federal reclassification to move forward under the new administration’s direction.. The Justice Department and the DEA have started an expedited administrative hearing process to consider broader rescheduling of marijuana from Schedule I to Schedule III.
That hearing is scheduled for late June. providing a formal stage for evaluating whether and how marijuana’s federal classification should change more generally.. In the background is an executive order signed by President Trump in December directing the attorney general to begin rulemaking to reschedule marijuana to Schedule III.
The administration is also pairing this effort with a separate policy push to boost research and ease restrictions around certain psychedelics. including ibogaine. which some countries use for PTSD treatment.. Taken together. these actions signal a broader shift toward treating certain controlled substances less as taboo and more as candidates for scientific review and regulated access.
Why Schedule III matters for patients and research
Schedule status isn’t just a label—it shapes funding, access, and what scientists can realistically study. Moving qualified marijuana products into Schedule III is designed to allow more research on safety and effectiveness, and to improve what physicians can rely on when making clinical decisions.
From a patient perspective, the biggest benefit is indirect but meaningful: better evidence.. If federal scheduling barriers ease for products that are already being made. tested. and dispensed under medical regimes. researchers may have a clearer route to study outcomes.. For doctors, clearer regulatory pathways can also translate into more consistent information, rather than relying on fragmented data.
Still, the scope of the change matters.. Because the order only applies to FDA-approved products and state-licensed medical marijuana. patients whose access depends on forms outside those categories may see no change in federal risk.. That unevenness could become a central point of debate—particularly as advocacy groups. state regulators. and medical providers try to determine what the federal government will do next.
State-licensed operators get a fast track—but compliance becomes tighter
The order also creates a fast-track process for state-licensed medical marijuana entities to register federally with the DEA. The Justice Department frames this as an efficient way to incorporate state licensing systems into the federal framework.
For state-licensed dispensaries and manufacturers. the shift could bring operational benefits by aligning federal oversight more closely with the way the industry already works in states that have medical marijuana programs.. It may also reduce some of the uncertainty that comes from operating under one set of federal restrictions while complying with another set of state rules.
There is also a potential knock-on effect for taxes and licensing costs in places that already legalized marijuana. where market participants have frequently argued that federal status affects how businesses finance. insure. and price products.. The order itself does not automatically remove taxes everywhere. but a lower classification could influence how regulators and markets treat these products.
The political fight over marijuana isn’t over
Marijuana policy has become a continuing political storyline that moves state-by-state, election-cycle-by-election-cycle. Decades of state action have steadily expanded legal medical and recreational markets, and the federal government’s stance has long lagged behind.
Thursday’s move suggests a strategy of partial accommodation: acknowledge the medical reality without immediately dismantling the federal prohibition framework.. That approach may appeal to policymakers who want to expand research and medical access while still preserving federal control over non-qualifying products.
But it also sets up a clear next question: whether broader rescheduling will follow the narrower order—and whether that broader change will ultimately satisfy the medical community’s demand for more consistent federal rules.. The late-June hearing will likely become the pivotal moment where the government decides how far it intends to go.
For now. the message from the Justice Department is specific: certain regulated marijuana products will face less federal restriction under Schedule III. research should expand. and the government is preparing to consider wider rescheduling—but the federal line remains firm for anything outside the qualifying categories.